Don't close this page .. Test is protected .. Answers cannot be changed .. We try now to connect to save and correct your answers.
Connection trial number:
If this message persists for long, please check your internet connection.
This test is monitored
Switching to another webpage or any other program is considered a cheating behavior and your test may be automatically terminated.
Okay
Important Notice
If you moved to the next question, you will not be able to come back to this question again.
Cancel
Move to next question
Final exam لمادة موضوعات مختارة في علم الادوية
Student data
×
Student data
Student name: ***
Student number: ***
Class or section: ***
Test instructions
×
Test instructions
عدد الاسءلة هي 63 سؤال
Page direction
×
Change page direction
Right to left
Left to right
Q1
Score: 0.5
A- Health
B- disease
C- organization
D- non the above
Q2
Score: 0.5
A- In vivo
B- in human
C- in animal
D- in vitro
Q3
Score: 0.5
A- Effect
B- Efficacy
C- Effectiveness
D- BENEFIT
Q4
Score: 0.5
A- Clark's Rule
B- Youngs Rule
C- creatinine clearance
D- non the above
Q5
Score: 0.5
A- chemical modification of known molecule
B- biotechnology and cloning
C- random screening for biological activity of large numbers of natural
D- all the above
Q6
Score: 0.5
A- drug action
B- cell
B- tissue
C- system
Q7
Score: 0.5
A- pregnancy
B- cough
C- diarrhea
D- heart
Q8
Score: 0.5
A- digoxin
B- NSAIDS
C- Atropine- like drugs
Q9
Score: 0.5
A- producing hypotension
B- producing hypoglycemia
C- producing hypertension
D- producing hyperglycemia
Q10
Score: 0.5
A- absorption
B- medication compliance
C- reduction in GI motility
D- Elimination
E- A+ D
F- all the above
Q11
Score: 0.5
A- Easily
B- with difficult
C- poorly
D- non of the above
Q12
Score: 0.5
صح
خطأ
Q13
Score: 0.5
صح
خطأ
Q14
Score: 0.5
A- chemical development
B- safety assessment
C- drug metabolism
D- all the above
Q15
Score: 0.5
A- strength of hypothesis
B- Availibility of target
C- market prediction
D- Toxicology
Q16
Score: 0.5
Q17
Score: 0.5
A- conducting a clinical trial
B- Analyzing the outcome of a clinical trial
C- Givrine permission so clinical trial
D- non the above
Q18
Score: 0.5
صح
خطأ
Q19
Score: 0.5
صح
خطأ
Q20
Score: 0.5
A- pharmacodynamic drug- drug interaction
B- pharmacokinetic drug- drug interaction
C- pharmaceutic interaction
Q21
Score: 0.5
A- dose
B- Age
C- systemic toxicity
D- Route
Q22
Score: 0.5
A- mental retardation
B- Hyperactivity
C- all the above
D- non of the above
Q23
Score: 0.5
A- pharmacodynamic
B- direct toxicity
C- genotoxicity
D- all the above
Q24
Score: 0.5
A- phase -1
B- phase- 2
Q25
Score: 0.5
A- sulfonamide
B- Aspirin
C- Mepiridine
D- Benzodiazepine
Q26
Score: 0.5
صح
خطأ
Q27
Score: 0.5
Q28
Score: 0.5
A- Elderly people
B- Infant
C- they are the major consumer of drug
D- include polypharmacy
Q29
Score: 0.5
A- poly pharmacy
B- multiple disease state
C- increase severity of illness
D- B+ C
E- all the above
Q30
Score: 0.5
A- gene
B- protein
C- cell
D- tissue
Q31
Score: 0.5
صح
خطأ
Q32
Score: 0.5
A- fetal period
B- organogenesis
C- Blastogenesis
D- non the above
Q33
Score: 0.5
صح
خطأ
Q34
Score: 0.5
A- nasal hypoplasia
B- bone stippling on X- Ray
C- depressed bridge of nose
D- all the above
E- non the above
Q35
Score: 0.5
A- spontaneous
B- route of exposure
C- species
D- sex of test animal formulation
Q36
Score: 0.5
A- digoxin
B- TCAS
C- Atropine like drugs
Q37
Score: 0.5
A- lethal dose to assayed in the same population
B- dose required for sub- lethal toxicity
C- all the above
Q38
Score: 0.5
صح
خطأ
Q39
Score: 0.5
صح
خطأ
Q40
Score: 0.5
صح
خطأ
Q41
Score: 0.5
A- check chemical stability
B- determine major metabolite
C- optimize and scale up synthesis and purification
D- produce GMP batches are required for biological and clinical test
Q42
Score: 0.5
A- transplant surgery
B- Apligraf
C- B cell
D- influenza
Q43
Score: 0.5
A- category A
B- category B
C- category c
D- category D
E- category x
Q44
Score: 0.5
A- phase I
B- phase II
C- phaseI and II and III and IV
D- phase III
Q45
Score: 0.5
A- Aspirin
B- sulfonamide
C- chloramphenicol
D- Tetracycline
Q46
Score: 0.5
A- structural
B- spontaneous
C- antidotal
D- route of exposure
Q47
Score: 0.5
Q48
Score: 0.5
Q49
Score: 0.5
Q50
Score: 0.5
A- 5- 10 years
B- 1 month
C- 15- 25 years
D- 9 month to 3 years
Q51
Score: 0.5
A- mental retardation
B- Mutagenesis
C- is seen in up to 25% of the fetuses with first - trimester exposure to coumarins
D- carcinogenesis
Q52
Score: 0.5
Q53
Score: 0.5
صح
خطأ
Q54
Score: 0.5
Q55
Score: 0.5
A- Arthritis
B-metabolism
C- peptic ulcer
D- stroke
Q56
Score: 0.5
صح
خطأ
Q57
Score: 0.5
A- animal
B- human
C- in vivo
Q58
Score: 0.5
صح
خطأ
Q59
Score: 0.5
صح
خطأ
Q60
Score: 0.5
A- vaccination
B- blood transfusion
C- transplantation
D- drug therapy
Q61
Score: 0.5
A- drugs
B- food additives
C- cosmetic
D- pesticide
E- all of the above
Q62
Score: 0.5
A- albumin
B- alpha-1 acid glycoproteins
C- T cell
Q63
Score: 0.5
صح
خطأ
Q64
Score: 0.5
صح
خطأ
Q65
Score: 0.5
صح
خطأ
Q66
Score: 0.5
A- pharmaceutic interaction
B- pharmacodynamic interaction
C- pharmacokinetic interaction
Q67
Score: 0.5
Q68
Score: 0.5
Q69
Score: 0.5
صح
خطأ
Q70
Score: 0.5
A- usually placebo controlled
B- phase IIa is exploratory and phase IIb is confirmatory
C- the opproxinate number of healthy subject is 50- 500
D- gives confirmation of clinical dose and regimen for efficacy
Q71
Score: 0.5
صح
خطأ
Q72
Score: 0.5
A- Antibodies
B- vaccines
C- enzyme
D- DNA product
Q73
Score: 0.5
صح
خطأ
Q74
Score: 0.5
A- result in polar
B- water soluble
C- oxidase
D- conjugation
Q75
Score: 0.5
A- urinary retention
B- hyperglycemia
C- heart block
D- GI hemorrhage
Q76
Score: 0.5
A- FDA
B- NMR
C- IND
Q77
Score: 0.5
Q78
Score: 0.5
Q79
Score: 0.5
A- treatment of pre- existing chronic disorder
B- always use drugs which have been widely used
C- over the counter
D- drugs for medical condition prior to confirmation of pregnancy
Q80
Score: 0.5
A- factor including the vascular perfusion
B- By 6 weeks of age
C- such as penicillin
D- are reduced by 50% in premature
Questions you haven't answered yet:
Are you sure you want to end this test and send your answers?
All copy rights reserved
©
arab-exams.com
2014-2023
Dismiss this alert